PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

Stanley Laman Group Ltd. cut its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.2% in the 3rd quarter, Holdings ...

Elevated Capital Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 6.7% during the 3rd ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

The UK's MHRA has approved Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty (KP.2), for use in adults. This approval ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In partnership with the Bill & Melinda Gates Foundation, BioNTech is developing vaccines for HIV and tuberculosis, and its flagship covid-19 vaccine Comirnaty was co-developed with Pfizer.

Pfizer faces near-term challenges as COVID-19 product sales decline. However, excluding Comirnaty and Paxlovid, revenue grew 14% operationally in Q2 2024. This result demonstrates the strength of ...

We recently compiled a list of the 10 Worst Performing Blue Chip Stocks in 2024. In this article, we are going to take a look ...